The activity of pergolide, an N-propylergoline derivative, has been tested for stimulation of central dopaminergic receptors. Binding to dopamine receptors shows that pergolide acts as an agonist with respect to these receptors. GTP decreases the potencies of dopamine agonists and of pergolide, It is now established that the major abnormality in parkinsonism is the degeneration of the nigrostriatal 3,4-dihydroxyphenylethylamine (dopamine) neurons. The effectiveness of 3,4-dihydroxyphenylalanine (L-dopa) in parklnsonism is dependent on the capacity of the remaining nigrostriatal dopamine neurons to synthesize dopamine from administered L-dopa. It has become apparent that therapeutic response diminishes after prolonged treatment with L-dopa (1, 2). This decrease might be due to progressive degeneration of the nigrostriatal dopamine neurons or to a decreased sensitivity of dopamine receptors in the striatum. It was therefore of interest to investigate the effectiveness of drugs that directly stimulate dopamine receptors in the brain. Among various dopamine agonists tested, certain ergot alkaloids were found to stimulate dopamine receptors (3, 4), and their therapeutic effectiveness in parkinsonism was investigated (5, 6).
It is now established that the major abnormality in parkinsonism is the degeneration of the nigrostriatal 3,4-dihydroxyphenylethylamine (dopamine) neurons. The effectiveness of 3,4-dihydroxyphenylalanine (L-dopa) in parklnsonism is dependent on the capacity of the remaining nigrostriatal dopamine neurons to synthesize dopamine from administered L-dopa. It has become apparent that therapeutic response diminishes after prolonged treatment with L-dopa (1, 2) . This decrease might be due to progressive degeneration of the nigrostriatal dopamine neurons or to a decreased sensitivity of dopamine receptors in the striatum. It was therefore of interest to investigate the effectiveness of drugs that directly stimulate dopamine receptors in the brain. Among various dopamine agonists tested, certain ergot alkaloids were found to stimulate dopamine receptors (3, 4), and their therapeutic effectiveness in parkinsonism was investigated (5, 6) .
We now describe dopamine agonist properties of a semisynthetic ergoline derivative, pergolide (8fl-[8-(methylthio)-methyl]-6-propylergoline), tested both in vitro and in two animal models that simulate certain features of parkinsonism. The potency of pergolide was compared with that of bromocriptine (2-bromo-a-ergocriptine), another ergot derivative currently used in the treatment of parkinsonism (7, 8) . The long duration of action of pergolide as an agonist (9, 10) prompted us to investigate its therapeutic effectiveness in parkinsonism patients. Preliminary reports on this study have been presented (9, 11, 12 Values for the mean inhibitory concentration, ICso, were derived by log probit analysis. Values for the dissociation constant, Kd, for each radioactive ligand were determined from the corresponding Scatchard plots, and values for the inhibitor constant, Ki, were determined according to the equation Ki = IC50/(I + C/Kd), in which C represents the concentration of the radioactive ligand.
Dopamine-Sensitive Adenylate Cyclase. Male SpragueDawley rats were sacrificed by decapitation, and striata were rapidly dissected. The activity of adenylate cyclase was determined in triplicate for each assay as described (14) . The final dilution of tissue was 1:300, 3',5'-cyclic AMP (cAMP) was measured by a protein-binding assay (15) , and protein was measured by the method of Lowry et al. (16) .
Surgical Lesions. Unilateral 6-OH-dopamine lesions were induced in and decortication was performed on male Sprague-Dawley rats weighing 150-200 g (17, 18) . Green monkeys (Cercopithecus sabeus) weighing 3-4 kg were used for placing unilateral radiofrequency ventromedial tegmental (VMT) lesions in the brain stem (19) . The animals developed hypokinesia and resting tremor (4-6 cycles per sec) 1-2 weeks after surgery (20) .
Turning Behavior. The turning behavior in rats was measured in a transparent plastic cage and the number of 3600 turns was recorded for 3 min every 15 min (17).
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Abbreviations: Spi, spiroperidol; NPA, N-n-propylnorapomorphine; cAMP, 3',5'-cyclic AMP; AIM, abnormal involuntary movements; VMT, ventromedial tegmental. (23) . Adenylate Cyclase Activity. Pergolide was found to stimulate directly the adenylate cyclase activity of rat striatal homogenates (Table 4 ). In the absence of GTP it produced a relatively small but significant increase in activity, with maximal stimulation at 1 MM. At higher concentrations this stimulatory effect was reversed, and at 100MM pergolide actually inhibited enzyme activity. In the presence of 1 ,M GTP, a concentration that did not significantly change basal cyclase activity or dopamine-sensitive cyclase activity, stimulation by pergolide was enhanced, with a maximal increase of 79% obtained at 1 MM. The stimulatory effect of 3 MM pergolide was completely antagonized by an equimolar concentration of the dopamine antagonist haloperidol, but not by molindone, an antagonist at sertonergic receptors. This implies that pergolide acts in a specific manner, and that this interaction is most likely with a dopaminergic receptor. Dopamine agonist activity in vivo Dopamine agonist activity of pergolide was evaluated in two animal models that simulate parkinsonism. The results are summarized in Table 5 . In rats with unilateral 6-OH-dopamine lesions of the nigrostriatal dopamine pathway, intraperitoneal administration of pergolide produces dose-dependent and long-lasting rotation contralateral to the lesion. At a dose of 0.05 mg/kg, turning behavior persists up to 8 hr and at a dose of 0.2 mg/kg up to at least 24 hr. Administration of haloperidol decreases the induced turning behavior in a dose-dependent manner.
In monkeys with VMT lesions, the intraperitoneal administration of pergolide results in a relief of tremor. Immediately after administration tremor disappears for several hours, and at a higher dose (0.2 mg/kg) longer than 24 hr. The relief of tremor is concomitant with the appearance of AIM, which persist for almost the entire tremor-free period.
DISCUSSION
The findings that GTP inhibits more effectively the displacement of [3H]Spi by pergolide in decorticated striatal membrane suggests that pergolide interacts with intrastriatal dopamine receptors that are linked to dopamine-sensitive adenylate cyclase. This idea is further corroborated with our findings that pergolide directly stimulates dopamine-sensitive adenylate cyclase in cell-free preparations. Thus, pergolide acts differently from other dopaminergic ergot compounds such as bromocriptine, Lergotrile, or Lisuride (24, 25) , which have been found to be ineffective in stimulating adenylate cyclase in striatal homogenates. More recently, it was reported that bromocriptine stimulates dopamine-sensitive adenylate cyclase in striatal slices (26) , but it remains to be determined whether this is a direct effect.
Evidence has been presented that GTP regulates the coupling between neurotransmitter receptors and adenylate cyclase. Thus, GTP in the presence of pergolide may interact with the coupling subunit and activate dopamine-sensitive adenylate cyclase activity in cell-free preparations. Indeed, the results of our study show that the stimulation of adenylate cyclase by pergolide is enhanced in the presence of GTP.
The most striking features of pergolide are its potency and its long-lasting action. Pergolide relieves tremor in monkeys with VMT lesions and induces turning behavior in rats with 6-OH-dopamine lesions of the nigrostriatal dopamine neurons for a longer time, at doses 1/10th to 1/20th of those of other dopaminergic ergot compounds. Furthermore, a single-dose administration of pergolide in humans results in an inhibition of prolactin secretion that persists for more than 24 hr (10). The long-lasting action of pergolide indicates that the drug is tightly bound to dopamine receptors or that the concentration in the vicinity of the receptors is maintained.
Because the ultimate test for the utility of a dopamine agonist is its anti-parkinsonism efficacy in humans, it was of considerable interest to evaluate this drug in parkinsonism. In preliminary clinical trials, pergolide was found to be effective in patients with advanced parkinsonism (27) . Particularly, pergolide was effective in attenuating the L-dopa-induced "onoff" phenomena (oscillation in performance) by increasing the time in which the patient could function actively.
It is assumed that decreased buffer capacity produced by progressive loss of nigrostriatal dopamine neurons in parkinsonism contributes to the "on-off" effect during treatment with L-dopa. These "on-off" phenomena are one of the major adverse effects occurring during L-dopa treatment. Thus, a potent dopamine agonist, such as pergolide, that has long duration of action and that does not require intact nigrostriatal dopamine neurons for its action should produce minimal fluctuation in performance. At present, therefore, pergolide seems to be a promising anti-parkinsonism agent.
After long-term treatment of rats (34 weeks) with pergolide, there is a significant decrease in the maximum number of
[3H]Spi binding sites (9) . These findings raise the question of the long-range efficacy of pergolide in parkinsonism. The biochemical studies reported here indicate that pergolide has a spectrum of action different from other dopaminergic ergots. It will therefore be of interest to determine which of these characteristics are responsible for its therapeutic efficacy and its propensity to develop undesirable side effects, such as AIM or mental changes (27) .
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